EDAP TMS to Exhibit Focal One® at AUA Annual Meeting
EDAP TMS SA (Nasdaq: EDAP), a prominent leader in robotic energy-based therapies, is set to exhibit the Focal One® system in unprecedented detail at the upcoming American Urological Association (AUA) Annual Meeting. This year’s event represents a remarkable milestone where the company will showcase its innovations to a wide audience of urology professionals.
Innovative Demonstrations and Hands-On Training
Participants can look forward to engaging activities, including expert-led demonstrations, semi-live procedures, and hands-on simulations of the Focal One platform. These experiences are designed to provide urologists with an immersive understanding of the technology, enhancing their expertise in focal therapy.
Significant Clinical Insights at AUA
The AUA meeting will feature an array of presentations, notably the final results from the FARP Study. This pivotal clinical trial compares ultrasound-based focal ablation with traditional radical prostatectomy, setting a new standard in evaluating treatment efficacy for early-stage prostate cancer.
Exciting Keynote on Remote Surgery
One of the highlights will be a presentation by Dr. Ruben Olivares from the Cleveland Clinic, who will discuss the groundbreaking remote transatlantic Focal One Robotic HIFU procedure. This pioneering work signifies a leap forward in surgical capabilities, demonstrating the potential for distance and accessibility in medical treatment.
Masterclass in Robotic HIFU
Leading up to the AUA Annual Meeting, EDAP TMS will host the first-ever Robotic Focal HIFU Masterclass at the University of Southern California. This event, taking place just days before the conference, will feature notable experts sharing their insights alongside live procedural demonstrations, providing urologists from around the globe a unique educational opportunity.
Growing Acceptance and Usage of Focal Therapy
The increasing number of scientific presentations dedicated to focal therapy and ablation at the AUA meetings underscores the treatment's growing acceptance in the urology community. EDAP TMS remains committed to demonstrating the potential of robotic HIFU technology in effective prostate cancer management.
About EDAP TMS SA
As a recognized leader in robotic energy-based therapies, EDAP TMS develops and manufactures minimally invasive medical devices that utilize ultrasound technology. The Focal One® system, introduced both in Europe and the US, stands as a testament to the company’s commitment to revolutionizing prostate cancer treatment through advanced technical solutions. With its robust capabilities and potential applications beyond prostate cancer, Focal One represents the forefront of treatment innovation.
Frequently Asked Questions
What is the Focal One® system?
The Focal One® system is a robotic platform used for focal therapy treatment of prostate cancer, utilizing ultrasound technology for precision and effectiveness.
When is the AUA Annual Meeting scheduled?
The AUA Annual Meeting is held annually, providing a platform for leaders in urology to share knowledge, research, and innovations.
What is the aim of the FARP Study?
The FARP Study aims to provide level-1 evidence comparing ultrasound-based focal ablation with robotic prostatectomy as a treatment for early-stage prostate cancer.
Who will present at the AUA Annual Meeting?
Notable presentations include Dr. Ruben Olivares discussing the first remote transatlantic Focal One Robotic HIFU procedure, among various experts showcasing their research.
What is EDAP TMS SA’s future vision?
EDAP TMS aims to expand the use of its robotic devices across multiple therapeutic indications, enhancing patient care and operational efficiencies in healthcare.
